DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Seth Gale - 1 Brian Snyder - 1 Eli Lilly - 1 Anne White - 1 Lilly - 1 Susan Kohlhaas - 1 Liana Apostolova - 1 White - 1
Top related locs:
Boston , Massachusetts U.S Amsterdam Eisai
Top related orgs:
Alzheimer Research - 1 Brigham - 1 Women’s - 1 REUTERS - 1 Alzheimer's Association International - 1 U.S . Food - 1 Drug Administration - 1 Alzheimer’s Research - 1

Search resuls for: "Seth Gale"


2 mentions found


☆ Lilly drug slows Alzheimer's by 60% for mildly impaired patients in trial
  + stars: | 2023-07-17 | by ( Deena Beasley | ) www.reuters.com   time to read: +5 min
Lilly expects the U.S. Food and Drug Administration to decide by the end of this year whether to approve donanemab. The company had previously reported that 24% of the overall donanemab treatment group had brain swelling. The deaths of three trial patients were linked to the treatment, researchers reported. For high tau patients, donanemab was shown to slow disease progression by about 17%, while the benefit was 35% for those with low-to-intermediate tau levels. Both medications are also being studied in large trials to see if they have an impact on delaying onset of Alzheimer's disease symptoms.
Persons: Seth Gale, Brian Snyder, Eli Lilly, Anne White, Lilly, Susan Kohlhaas, Liana Apostolova, White, Liz Coulthard, donanemab, Deena Beasley, Ludwig Burger, Will Dunham, Bill Berkrot, Caroline Humer Organizations: Alzheimer Research, Brigham, Women’s, REUTERS, Alzheimer's Association International, U.S . Food, Drug Administration, Alzheimer’s Research, Indiana University School of Medicine, Doctors, University of Bristol, JAMA, FDA, Alzheimer's Association, Health Organization, New York Stock Exchange, Thomson Locations: Boston , Massachusetts, U.S, Amsterdam, Eisai
☆ Lilly drug slows Alzheimer's progression by 35% in trial
  + stars: | 2023-05-03 | by ( Julie Steenhuysen Deena Beasley | Julie Steenhuysen | Deena Beasley | ) www.reuters.com   time to read: +4 min
The drug, donanemab, met all goals of the trial. "These are the strongest phase 3 data for an Alzheimer's treatment to date," said Maria Carrillo, chief science officer for the Alzheimer's Association. In the donanemab treatment group, Lilly said brain swelling, a known side effect of drugs of this type, occurred in 24% of the participants, with 6.1% experiencing symptoms. In the Leqembi Phase 3 trial, the drug was associated with brain swelling in nearly 13% of its study participants. It also said 47% of donanemab patients in the 18-month trial had no disease progression at 12 months, compared with 29% of the placebo group.
0 next >>
Total: 2